Neuroscientist's work leads to clinical trial for early Alzheimer's treatment | Cornell Chronicle
Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer’s. His research culminated in the Benfoteam clinical trial evaluating benfotiamine, a thiamine precursor, for slowing Alzheimer’s progression. The trial aims to determine the highest safe dose and its efficacy in improving cognition and global function.
Related Clinical Trials
Highlighted Terms
mild cognitive impairmentUniversity of CambridgeNCT06223360University of GothenburgdementiaAlzheimer's diseasebenfotiamineNational Institutes of HealthNational Institute of AgingAlzheimer's Disease Cooperative StudyBurke Neurological InstituteUniversity of VirginiaWeill Cornell MedicinethiamineC2N DiagnosticsColumbia University
Related News
Neuroscientist's work leads to clinical trial for early Alzheimer's treatment | Cornell Chronicle
Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer’s. His research culminated in the Benfoteam clinical trial evaluating benfotiamine, a thiamine precursor, for slowing Alzheimer’s progression. The trial aims to determine the highest safe dose and its efficacy in improving cognition and global function.